Genscript Biotech revenue and financials

1548 · HKEX · HKD

$30.48Change from previous close: +0.33%Absolute change: +$0.10

Close · November 16, 2026

In the fiscal year ended December 2025, Genscript Biotech reported revenue of $959.53M (+61.40% year over year). The net loss was $532.83M.

Annual revenue · 2025: $959.53M
  1. $114.74M2016
  2. $152.65M2017
  3. $231.02M2018
  4. $273.35M2019
  5. $390.85M2020
  6. $490.1M2021
  7. $625.7M2022
  8. $560.48M2023
  9. $594.49M2024
  10. $959.53M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+61.40%
2025 vs 2024
Net margin
-55.5%
2024: 498.2%

How Genscript Biotech is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue960594560626490391273231153115
Cost of revenue40632229032220813593.172.548.138.5
Gross profit55327227130428325618015910576.2
Selling, general and administrative22720919235230319712679.446.951.3
Research and development71.253.852.739035826318674.118.1—
Operating income2559.326.2-438-379-205-1315.139.624.9
EBIT2559.326.2-438-379-205-1315.139.624.9
EBITDA31870.083.5-389-342-175-11217.446.230.0
Interest expense17.38.05.713.32.41.40.80.1—0.0
Pre-tax income-471-171169-432-517-282-11422.738.532.5
Income tax61.93.06.0-3.71.0-0.53.81.911.56.0
Net income-5332,962-95.5-227-359-205-96.921.226.126.2
Net income to common shareholders-533-67.2423-227-359-205-96.921.226.126.2
Basic EPS-0.25-0.030.20-0.11-0.18-0.11-0.050.010.020.02
Diluted EPS-0.25-0.030.20-0.11-0.18-0.11-0.050.010.020.02
Average shares (basic)2,1672,1212,1092,0972,0311,9011,8541,7921,7141,667
Average shares (diluted)2,1922,1782,1092,0972,0311,9011,8541,8401,7291,709
Dividend per share—————————0.00

Companies in the group: same industry, similar size